Pharmaceutical

Roche’s U.S. subsidiary Genentech broke ground Monday on a $700 million plant tabbed for operation in 2029. The fill-finish plant, which will help pro...

After Maze Therapeutics opted not to participate in the National Advertising Division’s self-regulatory process for monitoring promotional claims, a c...

For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.

Ahead of plans to raise the price of its Type 2 diabetes and obesity blockbuster in the U.K. next month, Eli Lilly is temporarily halting Mounjaro ord...

Lawmakers in Virginia have approved proposed economic development packages for AstraZeneca and Eli Lilly to locate new manufacturing facilities in the...

The Leukemia & Lymphoma Society is marking Blood Cancer Awareness Month by rebranding and rolling out its first national advertising campaign in more...

The private-equity-owned company held off on a previously planned IPO in March due to market volatility.

Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s...

Artificial intelligence (AI) has quickly moved beyond being a buzzword in healthcare marketing—it’s now powering real change. In the latest episode of...

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.